FDA Proposes Reclassifying Digital Breast Tomosynthesis Systems from Class III to Class II

FDA's proposal would reduce regulatory burden for DBT systems by moving them from premarket approval to special controls with 510(k) pathway, while establishing new device classification and safety requirements. The Food and Drug Administration (FDA) is proposing to reclassify digital breast...